# TUB-040

Source: https://onco.cc/drugs/tub-040/  
OnCo record `tub-040` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TUB-040 is an experimental antibody-drug conjugate from Tubulis (Gilead), in phase 2 trials for platinum-resistant ovarian cancer, non-small cell lung cancer and endometrial cancer.

## Summary

TUB-040 is an antibody-drug conjugate from Tubulis (Gilead), with Gilead Sciences as acquirer. An IgG1 antibody against NaPi2b joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with Tubulis's P5 conjugation chemistry, with a drug-to-antibody ratio of 8. Its furthest stage is phase 2, for platinum-resistant ovarian cancer, non-small cell lung cancer (adenocarcinoma) and endometrial cancer. ClinicalTrials.gov registers it in 4 studies linked below. Tubulis pipeline page: Phase 1/2a (NAPISTAR 1-01, NCT06303505); Gilead acquisition release says Phase 1b/2. Highest registered stage is phase 2 (NCT07806773, phase 2a dose optimisation in NSCLC, not yet recruiting). FDA Fast Track for platinum-resistant ovarian cancer per Tubulis. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: TUB-040
- Modality: Antibody-drug conjugate
- Mechanism: An IgG1 antibody against NaPi2b joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with Tubulis's P5 conjugation chemistry, with a drug-to-antibody ratio of 8.

## Sources

- Tubulis (Gilead): tubulis.com: https://tubulis.com/our-pipeline/
- Tubulis (Gilead): tubulis.com: https://tubulis.com/our-pipeline/
- Tubulis (Gilead): tubulis.com: https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/
- Tubulis (Gilead): clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07743541
- ClinicalTrials.gov: trials of TUB-040: https://clinicaltrials.gov/search?intr=TUB-040

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- targets: [SLC34A2](https://onco.cc/targets/slc34a2/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)
- trials: [FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC](https://onco.cc/trials/nct06303505/), [Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer](https://onco.cc/trials/nct07736937/), [Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct07806773/), [Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy](https://onco.cc/trials/nct07743541/)

---
JSON: https://onco.cc/api/v1/entities/tub-040.json